Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive entities : Amgen inc. save search
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
Published: 2024-01-29 (Crawled : 09:00) - globenewswire.com
ALVO | $13.32 0.76% 0.75% 180K
|
n/a
|
| O: 2.39%
H: 4.67%
C: 1.67%
KMDA | $5.05 -0.99% 8K
|
Health Technology
|
| O: -1.05%
H: 0.41%
C: -0.35%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: -0.11%
H: 0.7%
C: 0.65%
avt03 prolia biosimilar positive results study
Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
Published: 2023-01-27 (Crawled : 13:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: 0.0%
H: 0.63%
C: -0.74%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: -0.0%
H: 0.25%
C: -0.48%
treatment chmp psoriasis positive
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial
Published: 2022-09-19 (Crawled : 06:00) - globenewswire.com
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
|
| O: -0.52%
H: 0.69%
C: 0.62%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: -0.22%
H: 0.1%
C: 0.05%
biosimilar trial positive
LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER
Published: 2022-09-11 (Crawled : 00:00) - prnewswire.com
MS | News 0 d | $92.09 1.58% 0.01% 7.3M
|
Finance
|
| O: 0.6%
H: 1.16%
C: 0.17%
CCXI | News | $51.99 -0.04%
|
Health Technology
|
| O: -0.16%
H: 0.16%
C: 0.06%
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: -1.88%
H: 3.78%
C: 3.73%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
lumakras lung trial positive cancer
AMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST)
Published: 2022-09-08 (Crawled : 14:20) - biospace.com/
CCXI | News | $51.99 -0.04%
|
Health Technology
|
| O: -0.16%
H: 0.47%
C: 0.35%
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: -0.69%
H: 2.52%
C: 2.52%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: 0.0%
H: 0.49%
C: 0.27%
otezla positive
AMGEN TO PRESENT NEW, POSITIVE CLINICAL AND REAL-WORLD DATA ACROSS INFLAMMATION PORTFOLIO AT EADV 2022
Published: 2022-08-30 (Crawled : 14:00) - biospace.com/
CCXI | News | $51.99 -0.04%
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: 0.76%
H: 0.37%
C: -1.8%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: 0.21%
H: 0.18%
C: -0.32%
positive
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 959, BIOSIMILAR CANDIDATE TO SOLIRIS® (ECULIZUMAB)
Published: 2022-08-23 (Crawled : 14:00) - biospace.com/
CCXI | News | $51.99 -0.04%
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: -0.57%
H: 1.88%
C: 0.59%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: -0.9%
soliris candidate biosimilar positive results study
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a)
Published: 2022-05-31 (Crawled : 17:00) - biospace.com/
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: 4.16%
H: 3.44%
C: -1.66%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: -0.1%
H: 0.89%
C: 0.68%
topline positive phase 2
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB)
Published: 2022-04-18 (Crawled : 22:00) - biospace.com/
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: -1.9%
H: 0.12%
C: -3.78%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: 0.0%
stelara biosimilar positive results phase 3 topline
Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis
Published: 2021-12-01 (Crawled : 22:00) - biospace.com/
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: 3.7%
H: 3.74%
C: -0.91%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: 0.78%
H: 2.59%
C: 0.18%
psoriasis positive results phase 3 topline
LUMYKRAS® (sotorasib) Receives Positive Opinion From EMA CHMP For Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: 1.02%
H: 0.0%
C: 0.0%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: 0.0%
ema lung cancer positive cancer chmp
Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR Conference Session
Published: 2021-10-06 (Crawled : 14:00) - biospace.com/
ENTX | $2.1 5.53% 5.24% 170K
|
Health Technology
|
| O: 0.44%
H: 2.39%
C: -2.61%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: -0.25%
H: 0.36%
C: -0.63%
phase 2 bone positive conference
Amgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG 451/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis At EADV Congress
Published: 2021-10-02 (Crawled : 12:20) - prnewswire.com
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
| Email alert
Add to watchlist
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
| Email alert
Add to watchlist
phase 2 positive dermatitis atopic dermatitis
Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)
Published: 2021-04-23 (Crawled : 18:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -0.03%
H: 0.95%
C: -0.44%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: -0.03%
H: 1.24%
C: 0.8%
positive phase 3 psoriasis
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.